Product Description
For the treatment of adult patients with acute bacterial skin and skin structure infections (ABSSSIs) caused by sensitive Gram-positive bacteria, including methicillin-resistant Staphylococcus aureus (MRSA)
AI Product Description
*The following content is generated by AI and is for reference only.
Oritavancin is a semi-synthetic lipoglycopeptide antibiotic derived from the naturally occurring vancomycin. Its chemical structure features a unique dimeric backbone linked by a disulfide bond, with a hydrophobic side chain attached to enhance membrane interaction. The molecular formula of oritavancin is C74H90Cl2N10O26S2, and it is registered under the CAS number 318852-88-7. This compound represents a significant advancement in the treatment of Gram-positive bacterial infections, particularly those caused by methicillin-resistant Staphylococcus aureus (MRSA).
The primary clinical application of oritavancin is the management of acute bacterial skin and skin structure infections (ABSSSI) caused by susceptible isolates of specific Gram-positive bacteria. Unlike traditional glycopeptides such as vancomycin, which require prolonged intravenous infusions over several days, oritavancin offers a distinct pharmacokinetic profile that allows for a single-dose administration. This unique dosing regimen provides substantial benefits for patients and healthcare systems by reducing hospital stays, minimizing the need for central venous catheters, and improving patient compliance.
Mechanistically, oritavancin exerts its bactericidal effect through two synergistic pathways. First, it binds to the D-alanyl-D-alanine termini of peptidoglycan precursors, inhibiting cell wall synthesis similarly to vancomycin. Second, and more critically, its lipophilic side chain enables the molecule to insert into the bacterial cell membrane, causing rapid depolarization and loss of membrane potential. This dual mechanism contributes to its potent activity against resistant strains and reduces the likelihood of developing resistance compared to monotherapy agents.
Despite its efficacy, oritavancin usage requires careful monitoring due to potential interactions with coagulation tests, specifically those involving activated partial thromboplastin time (aPTT), as the drug can interfere with these assays for up to 120 hours post-administration. Furthermore, while generally well-tolerated, common adverse reactions include nausea, headache, and infusion site reactions. Oritavancin remains a crucial tool in the antimicrobial armamentarium, addressing the growing global threat of multidrug-resistant Gram-positive pathogens with a convenient and effective therapeutic approach.